ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Astellas at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Astellas takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1054. Its program centres on stomach and gastroesophageal junction cancers that carry the CLDN18.2 marker. It also covers why the first treatment choice matters in advanced prostate cancer and urothelial cancer of the bladder and urinary tract.

OrganizationESMO 2026 Attendance
Astellas
Tokyo, Japan
Large pharmaExhibitor
Japanese pharmaceutical company whose oncology medicines include enzalutamide, enfortumab vedotin and zolbetuximab.
Booth
Exhibiting at Booth 1054
Satellite
Fri Oct 23
18:15–19:45
Astellas - Solving the puzzle: Optimising practice in CLDN18.2+ gastric/GEJ adenocarcinoma
Sponsored session · with Hospital Universitario de Navarra
Gastrointestinal cancers
Satellite
Sun Oct 25
13:00–14:30

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Astellas

Tell us what you sell and we’ll find the people at Astellas most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction